Results 111 to 120 of about 578,179 (195)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors

Frontiers in Immunology, 2021
C. I. Edvard Smith, Jennifer R. Brown, Rula Zain, Rula Zain   +3 more
doaj   +1 more source

Building an Interleukin‐10‐Producing Identity: How B Cells Acquire Interleukin‐10 Competence and How Plasma Cell Differentiation Consolidates This Program

Immunological Reviews, Volume 343, Issue 1, October 2026.
ABSTRACT Interleukin (IL)‐10‐producing B cells represent an archetype for the regulatory functions of B cells. Here, we review the cell‐surface receptors and transcriptional regulators that control IL‐10 expression in B cells and enable their regulatory function in vivo.
Bui Thi Cuc, Yanli Tong, Zhiguo Wu, Daniel Alvarez‐Simon, Simon Fillatreau   +4 more
wiley   +1 more source

"Screening of the Bruton Tyrosine Kinase (BTK) Gene Mutations in 13 Iranian Patients with Presumed X-Linked Agammaglobulinemia "

Iranian Journal of Allergy, Asthma and Immunology, 2004
X-linked agammaglobulinemia (XLA) is an immunodeficiency caused by mutations in the Bruton tyrosine kinase (Btk) gene. In order to identify the mutations in Btk gene in Iranian patients with antibody deficiency, 13 male patients with an XLA phenotype ...
"Asghar Aghamohammadi, Nima Parvaneh, Hirokazu Kanegana, Mostafa Moin, Ali Akbar Amirzargar, Abolhassan Farhoudi, Zahra Pourpak, Masoud Movahedi, Mohammad Gharagozlou, Nima Rezaei, Takeshi Futatani, Toshio Miyawaki "   +11 more
doaj  

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis

ImmunoTargets and Therapy, 2021
Laura C Arneson,1,* Kristen J Carroll,1,* Eric M Ruderman2 1Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School ...
Arneson LC, Carroll KJ, Ruderman EM
doaj  

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

International Journal of Cancer, Volume 159, Issue 6, Page 1499-1509, 15 September 2026.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Xingtong Wang, Yangzhi Zhao, Zhaoxia Li, Chengqian Chen, Yang Song, Ou Bai   +10 more
wiley   +1 more source

Aminopyrazole Carboxamide Bruton’s Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning

, 2018
Potent covalent inhibitors of Bruton’s tyrosine kinase (BTK) based on an aminopyrazole carboxamide scaffold have been identified. Compared to acrylamide-based covalent reactive groups leading to irreversible protein adducts, cyanamide-based reversible ...
Zhao-Kui Wan (2004907), Brian M. Juba (4587880), John I. Trujillo (2299687), Jeffrey F. Ohren (2189149), Stephen E. Benoit (6054389), Kyung-Hee Kim (617163), Arthur J. Wittwer (6054410), John Douhan (6054416), Nelson Huang (2438155), Thomas N. O’Connell (6054404), Erica Liu (5585105), Christoph W. Zapf (2019895), Nicole Caspers (1811215), Daniel P. Walker (2124721), Robert O. Hughes (2139538), Mihir D. Parikh (3840538), Venkataraman Thanabal (2367781), Mark E. Schnute (2122345), Erin McCarthy (6054395), John R. Springer (6054407), Joy S. Miyashiro (6054398), Rajeev Hotchandani (2351023), Jane M. Withka (2025886), Li Xing (35790), Shaun R. Selness (2363620), Nancy L. Wood (6054413), Margaret L. Grapperhaus (3011067), Seungil Han (1811221), Dean Messing (5730854), Ingrid P. Buchler (6054392), Shashi Mohan (6054401), Michelle Schmidt (2122342)   +31 more
core   +1 more source

Mycoplasma pneumonia in a patient with X-linked agammaglobulinemia

BMC Infectious Diseases
Background X-linked agammaglobulinemia (XLA), also referred to as Bruton’s tyrosine kinase deficiency, is a rare genetic disorder that affects the immune system.
Bowen Dai, Shujuan Han, Yuanfang Shen, Zhi Li, Shouhang Chen, Zhuangzhuang Wang, Yan Yuan, Ruyu Zhang, Chenyu Wang, Jiaying Zheng, Qiujing Liang, Qingmei Wang, Yaodong Zhang, Xiaolong Zhang, Fang Wang, Yuefei Jin   +15 more
doaj   +1 more source

Profound Sinoatrial Arrest Associated with Ibrutinib

Case Reports in Oncological Medicine, 2017
Background. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for second-line treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström macroglobulinemia.
Kanupriya Mathur, Aditya Saini, Kenneth A. Ellenbogen, Richard K. Shepard   +3 more
doaj   +1 more source

Intermolecular interactions between the SH3 domain and the proline-rich TH region of Bruton’s tyrosine kinase [PDF]

, 2001
The SH3 domain of Bruton’s tyrosine kinase (Btk) is preceded by the Tec homology (TH) region containing proline-rich sequences. We have studied a protein fragment containing both the Btk SH3 domain and the proline-rich sequences of the TH region (PRR-SH3)
Torleif Härd, Okoh, MP, Michael P Okoh, Mauno Vihinen, Vihinen, M, Hansson, H, Vihinen, Mauno, Härd, T, Smith, C.I.Edvard, Okoh, Michael P, C.I.Edvard Smith, Hansson, Henrik, Härd, Torleif, Smith, CIE, Henrik Hansson   +14 more
core   +1 more source

Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging

Kinases and Phosphatases
Bruton’s tyrosine kinase (BTK) is a key signaling molecule involved in both hematological malignancies and solid tumors. In B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), BTK mediates B-cell receptor ...
Zahraa Qusairy, Miran Rada
doaj   +1 more source